文献速递认知障碍与痴呆

唐氏综合征与常染色体显性阿尔茨海默病的横断面FDG比较

Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease.
PubMed 文献 · Ann Neurol · 2025-09-22

本研究比较唐氏综合征(DS,n=76)与常染色体显性阿尔茨海默病(ADAD,n=297)及神经典型家族对照(n=188)的脑FDG PET摄取模式。结果显示DS在预期症状出现前20年FDG摄取已降低,而ADAD在预期症状出现前7年才与对照出现差异;淀粉样蛋白负荷越高FDG越低,但两种遗传形式的下降模式不同。

要点

  • DS在预期症状出现前20年即出现FDG摄取降低,早于ADAD。
  • ADAD基线FDG在预期症状出现前7年才与对照出现差异。
  • 两种遗传形式淀粉样蛋白阳性者FDG下降速率相似但模式不同。

核心结论

  • DS患者脑葡萄糖代谢显著降低,即使在认知稳定者中亦然。
  • DS与ADAD的FDG下降模式不同,FDG-PET诊断效用具有遗传形式特异性。

研究设计与样本

  • 横断面分析,DS来自ABC-DS队列(n=76),ADAD来自DIAN队列(n=297),神经典型家族对照来自DIAN(n=188)。
  • 采用组内线性回归和广义相加模型分析特定区域FDG摄取,纳入年龄、性别、APOE ε4状态和皮层淀粉样蛋白负荷。

主要发现

  • DS在预期症状出现前20年FDG摄取即低于神经典型家族对照(p < 0.01)。
  • ADAD基线FDG在预期症状出现前7年之前与神经典型家族对照相似。
  • DS和ADAD症状性个体FDG均低于神经典型家族对照(p < 0.01)。
  • 两种遗传形式中较高的淀粉样蛋白负荷均与较低的FDG相关,淀粉样蛋白阳性的DS和ADAD FDG下降速率相似。

临床怎么用

  • FDG-PET解读需考虑阿尔茨海默病的遗传形式,DS与ADAD的代谢下降模式不同。
  • DS患者即使认知稳定也应关注脑葡萄糖代谢降低的早期迹象。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Directly compare the brain glucose patterns seen with [F-18] fluorodeoxyglucose (FDG) positron emission tomography (PET) between 2 genetically determined forms of Alzheimer's disease: Down syndrome (DS) and autosomal dominant Alzheimer's disease (ADAD). METHODS: Cross-sectional analyses of FDG were performed in individuals with DS (n = 76) from the Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS), ADAD (n = 297), and neurotypical familial controls (n = 188) from the Dominantly Inherited Alzheimer Network (DIAN). Within-group linear regression models and generalized additive models were performed for select regional FDG uptake measures (isthmus cingulate and inferior parietal, precuneus, middle temporal gyrus, and precentral gyrus). Age, sex, apolipoprotein (APOE) ε4 carrier status, and cortical amyloid burden were included within these analyses. RESULTS: Even 20 years before expected onset of clinical symptoms, FDG uptake was lower for DS compared to neurotypical familial controls (p < 0.01). ADAD baseline FDG was similar to neurotypical familial controls until 7 years before expected symptom onset. Both symptomatic individuals with DS and ADAD had lower FDG compared to neurotypical familial controls (p < 0.01). A higher amyloid burden was associated with lower FDG for both genetic forms, with similar rates of decline in FDG uptake for DS and ADAD who were amyloid positive. INTERPRETATION: Brain glucose metabolism is substantially lower for people with DS, even in individuals who are cognitively stable. The patterns of FDG decline are distinct in these 2 genetically determined forms of AD. The diagnostic utility of FDG-PET is specific to the genetic form of AD. ANN NEUROL 2025;98:1237-1248.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Abdelmoity O, Wisch JK, Kennedy JT, et al. Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease. Ann Neurol. 2025. PMID: 40977577. doi:10.1002/ana.78002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。